HBM Healthcare Invests in Harmony Biosciences’ $270 Million Equity Financing

Palo Alto – October 30, 2017 – Cooley advised HBM Healthcare Investments and certain other investors on their lead investment in Harmony Biosciences’ completed $270 million equity financing. Harmony used the proceeds of the funding to acquire exclusive US rights from French company Bioproject to develop, register and market pitolisant – a drug approved by the EU for the treatment of narcolepsy. Cooley partner Mehdi Khodadad led the team advising HBM.

“We’re excited to research, develop and see US approval for pitolisant, a potential first-in-class therapy to treat patients with narcolepsy,” said Harmony CEO Bob Repella in a news release. “In addition to working with the FDA, Harmony will be working closely with healthcare providers, advocacy organizations and other stakeholders to help address the unmet needs of the patient community.” 

Headquartered in Plymouth Meeting, Pennsylvania, Harmony is dedicated to developing innovative therapies to help patients with unmet medical needs. Harmony focuses on providing novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. 

HBM Healthcare Investments actively invests in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas with a track-record of more than 100 biopharma and healthcare investments that have resulted in significant value creation via sale transactions and IPOs since inception. 

Cooley serves as primary counsel to HBM and its fund affiliates on their portfolio investments.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900 lawyers across 12 offices in the United States, China and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.